4BIO Capital leads oversubscribed $28.4 million Series A financing of March Biosciences March Bio is rapidly advancing its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy, MB-105, in development for the treatment of relapsed and refractory CD5 positive T-cell...